Coherus BioSciences Gross Profit Over Time
| CHRS Stock | USD 1.26 0.02 1.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Coherus BioSciences Performance and Coherus BioSciences Correlation. Coherus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coherus BioSciences. If investors know Coherus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coherus BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.09) | Revenue Per Share 2.678 | Quarterly Revenue Growth (0.05) | Return On Assets (0.14) |
The market value of Coherus BioSciences is measured differently than its book value, which is the value of Coherus that is recorded on the company's balance sheet. Investors also form their own opinion of Coherus BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Coherus BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coherus BioSciences' market value can be influenced by many factors that don't directly affect Coherus BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coherus BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Coherus BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coherus BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Coherus BioSciences and related stocks such as Assembly Biosciences, Spero Therapeutics, and Achilles Therapeutics PLC Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASMB | 0.0 | 0.0 | 0.0 | 0.0 | (24 M) | (65 K) | (80.3 K) | (35.2 M) | (57.9 M) | 16 M | 79 M | 5.8 M | (498 K) | (41.7 M) | (39.7 M) |
| SPRO | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | 335 K | 2 M | 4 M | 4.7 M | 9.3 M | 17.1 M | 47 M | 96.4 M | 101.2 M |
| ACHL | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (778 K) | (3.3 M) | (3.7 M) | (4.7 M) | (4.5 M) |
| TIL | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | 138 K | (2.8 M) | (6 M) | (4.8 M) | (4.5 M) |
| NXTC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (19.8 M) | 6.3 M | 22.4 M | (4.3 M) | (4.5 M) | (3.7 M) | (3.5 M) |
| NUVB | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (103 K) | (368 K) | (484 K) | (222 K) | (233.1 K) |
| CTMX | 888 K | 888 K | 888 K | 888 K | 5.1 M | 7.7 M | 15 M | 71.6 M | 59.5 M | 57.5 M | 100.4 M | 69.6 M | 53.2 M | 101.2 M | 54.2 M |
| BOLT | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (40.1 M) | (2.4 M) | 838 K | 6 M | 6.3 M |
Coherus BioSciences and related stocks such as Assembly Biosciences, Spero Therapeutics, and Achilles Therapeutics PLC Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Coherus BioSciences minus its cost of goods sold. It is profit before Coherus BioSciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Coherus BioSciences | CHRS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.26
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.